Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2019 Jul 2;144:106353. doi: 10.1016/j.prostaglandins.2019.106353

Figure 9. EP3 antagonist modestly increases hepatic lipid staining in mice fed VHFD.

Figure 9.

A. H&E staining of livers showed that dietary fat increased steatosis. No noticeable effect of DG-041 treatment on steatosis was observed. In VHFD mice treated with DG-041, hepatocellular ballooning was observed. B. Liver ORO staining was increased with increasing dietary fat. DG-041 appeared to increase ORO staining only in mice fed the VHFD. Images are a representative sample of sections from 4 control + vehicle, 3 control + DG-041, 3 HFD + vehicle, 4 HFD + DG-041, 4 VHFD + vehicle, 5 VHFD + DG-041.